(Total Views: 431)
Posted On: 09/28/2021 3:20:22 PM
Post# of 154157
Re: onestepahead #105927
Good find.
Aduhelm was approved by the FDA for Alzheimer's despite showing no improvement in the disease only a reduction in amyloid beta plaque. There is no consensus that amyloid beta plaque causes Alzheimer's.
What they propose in the paper you posted is that a lipoprotein/amyloid beta protein compound causes vascular inflammation allowing blood brain barrier leakage and the introduction of the compound to the brain causing inflammation in the brain.
Most likely the brain inflammation itself is the culprit. Leronlimab would do two things. Reduce inflammation in the brain and shut down vascular leakage blocking the lipoprotein/amyloid beta protein compound from passing through the blood brain barrier.
Aduhelm was approved by the FDA for Alzheimer's despite showing no improvement in the disease only a reduction in amyloid beta plaque. There is no consensus that amyloid beta plaque causes Alzheimer's.
What they propose in the paper you posted is that a lipoprotein/amyloid beta protein compound causes vascular inflammation allowing blood brain barrier leakage and the introduction of the compound to the brain causing inflammation in the brain.
Most likely the brain inflammation itself is the culprit. Leronlimab would do two things. Reduce inflammation in the brain and shut down vascular leakage blocking the lipoprotein/amyloid beta protein compound from passing through the blood brain barrier.
(12)
(0)
